17255138|t|Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
17255138|a|OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen. METHODS: We conducted a retrospective cohort study using administrative data of patients > or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures. RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic.
17255138	22	38	COX-2 inhibitors	ChemicalEntity	D052246
17255138	56	62	NSAIDs	ChemicalEntity	D000894
17255138	188	215	acute myocardial infarction	DiseaseOrPhenotypicFeature	D009203
17255138	217	220	AMI	DiseaseOrPhenotypicFeature	D009203
17255138	227	243	COX-2 inhibitors	ChemicalEntity	D052246
17255138	324	361	non-steroidal anti-inflammatory drugs	ChemicalEntity	D000894
17255138	363	369	NSAIDs	ChemicalEntity	D000894
17255138	425	428	AMI	DiseaseOrPhenotypicFeature	D009203
17255138	433	444	GI bleeding	DiseaseOrPhenotypicFeature	D006471
17255138	459	467	patients	OrganismTaxon	9606
17255138	474	490	COX-2 inhibitors	ChemicalEntity	D052246
17255138	495	501	NSAIDs	ChemicalEntity	D000894
17255138	506	519	acetaminophen	ChemicalEntity	D000082
17255138	601	609	patients	OrganismTaxon	9606
17255138	662	667	NSAID	ChemicalEntity	D000894
17255138	671	684	acetaminophen	ChemicalEntity	D000082
17255138	838	845	aspirin	ChemicalEntity	D001241
17255138	862	875	acetaminophen	ChemicalEntity	D000082
17255138	887	896	rofecoxib	ChemicalEntity	C116926
17255138	907	916	celecoxib	ChemicalEntity	C105934
17255138	935	941	NSAIDs	ChemicalEntity	D000894
17255138	958	965	aspirin	ChemicalEntity	D001241
17255138	988	997	rofecoxib	ChemicalEntity	C116926
17255138	1009	1018	celecoxib	ChemicalEntity	C105934
17255138	1032	1038	NSAIDs	ChemicalEntity	D000894
17255138	1053	1066	acetaminophen	ChemicalEntity	D000082
17255138	1087	1094	aspirin	ChemicalEntity	D001241
17255138	1172	1175	AMI	DiseaseOrPhenotypicFeature	D009203
17255138	1186	1199	acetaminophen	ChemicalEntity	D000082
17255138	1209	1216	aspirin	ChemicalEntity	D001241
17255138	1230	1239	rofecoxib	ChemicalEntity	C116926
17255138	1259	1268	celecoxib	ChemicalEntity	C105934
17255138	1288	1296	naproxen	ChemicalEntity	D009288
17255138	1316	1326	diclofenac	ChemicalEntity	D004008
17255138	1349	1358	ibuprofen	ChemicalEntity	D007052
17255138	1393	1400	aspirin	ChemicalEntity	D001241
17255138	1413	1422	rofecoxib	ChemicalEntity	C116926
17255138	1442	1451	celecoxib	ChemicalEntity	C105934
17255138	1471	1480	ibuprofen	ChemicalEntity	D007052
17255138	1500	1510	diclofenac	ChemicalEntity	D004008
17255138	1530	1538	naproxen	ChemicalEntity	D009288
17255138	1561	1574	acetaminophen	ChemicalEntity	D000082
17255138	1625	1632	aspirin	ChemicalEntity	D001241
17255138	1634	1642	naproxen	ChemicalEntity	D009288
17255138	1680	1683	AMI	DiseaseOrPhenotypicFeature	D009203
17255138	1684	1695	GI bleeding	DiseaseOrPhenotypicFeature	D006471
17255138	1701	1704	AMI	DiseaseOrPhenotypicFeature	D009203
17255138	1705	1716	GI toxicity	DiseaseOrPhenotypicFeature	D005767
17255138	1720	1729	celecoxib	ChemicalEntity	C105934
17255138	1753	1766	acetaminophen	ChemicalEntity	D000082
17255138	1805	1814	rofecoxib	ChemicalEntity	C116926
17255138	1822	1828	NSAIDs	ChemicalEntity	D000894
17255138	1845	1852	aspirin	ChemicalEntity	D001241
17255138	1859	1868	celecoxib	ChemicalEntity	C105934
17255138	1873	1881	naproxen	ChemicalEntity	D009288
17255138	Association	D005767	C105934	Novel
17255138	Association	D005767	C116926	Novel
17255138	Association	D005767	D000082	Novel
17255138	Association	D005767	D000894	Novel
17255138	Positive_Correlation	D009288	D006471	Novel
17255138	Positive_Correlation	D009288	D009203	Novel
17255138	Positive_Correlation	D009203	D052246	No
17255138	Association	C105934	D006471	Novel
17255138	Association	C105934	D009203	Novel
17255138	Association	C116926	D006471	Novel
17255138	Association	C116926	D009203	Novel
17255138	Association	D000082	D006471	Novel
17255138	Association	D000082	D009203	Novel
17255138	Negative_Correlation	D001241	C105934	Novel
17255138	Negative_Correlation	D001241	C116926	Novel
17255138	Negative_Correlation	D001241	D000082	Novel
17255138	Negative_Correlation	D001241	D000894	Novel
17255138	Association	D000894	D009203	Novel
17255138	Comparison	D000894	D000082	Novel
17255138	Comparison	D052246	D000082	Novel
17255138	Comparison	D052246	D000894	Novel